Comparison of Analgesic Effects of ACB Versus ACB Combined With BiFeS Block in ACL Reconstruction Surgery

October 5, 2026 updated by: Atakan Sezgi, Ankara Etlik City Hospital

Comparison of Postoperative Analgesic Effects of Adductor Canal Block Versus Adductor Canal Block Combined With Biceps Femoris Short Head Block in Patients Undergoing Anterior Cruciate Ligament Reconstruction Surgery

Anterior cruciate ligament (ACL) reconstruction is commonly associated with moderate to severe postoperative pain, particularly during the early postoperative period and rehabilitation. Effective postoperative analgesia is important to facilitate early mobilization, improve patient comfort, and reduce opioid consumption and opioid-related adverse effects.

Adductor canal block (ACB) is commonly used as part of multimodal analgesia for knee surgery because it provides analgesia while largely preserving quadriceps motor function. However, ACB primarily targets the anteromedial aspect of the knee and may provide limited analgesia for pain arising from the posterior and posterolateral knee.

The biceps femoris short head (BiFeS) block is a motor-sparing fascial plane block targeting sensory contributions to the posterolateral knee region. Combining BiFeS block with ACB may therefore provide more comprehensive analgesia than ACB alone.

This randomized study aims to compare the postoperative analgesic efficacy of adductor canal block alone with adductor canal block combined with BiFeS block in patients undergoing anterior cruciate ligament reconstruction surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18-65 years
  • Patients scheduled for elective unilateral anterior cruciate ligament reconstruction surgery
  • American Society of Anesthesiologists physical status I-III
  • Patients who provide written informed consent

Exclusion Criteria:

  • Age <18 or >65 years
  • ASA physical status IV or higher
  • Coagulopathy or ongoing anticoagulant therapy incompatible with peripheral nerve block
  • Infection at the block injection site
  • Patient refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Adductor Canal Block Group

After induction of general anesthesia, an ultrasound-guided adductor canal block will be performed on the operative side. A linear ultrasound transducer will be placed transversely over the mid-thigh to identify the sartorius muscle, femoral artery, vastus medialis muscle, and adductor canal. A block needle will be advanced using an in-plane technique. After negative aspiration, 10 mL of 0.25% bupivacaine will be injected into the adductor canal. Appropriate spread of the local anesthetic will be confirmed by ultrasound imaging.

All patients will receive standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intravenous dexketoprofen 50 mg twice daily.

Ultrasound-guided adductor canal block will be performed using 10 mL of 0.25% bupivacaine.

Active Comparator: Adductor Canal Block + BiFeS Block Group

After induction of general anesthesia, an ultrasound-guided adductor canal block will first be performed on the operative side using the same technique as in the adductor canal block group.

Subsequently, an ultrasound-guided biceps femoris short head (BiFeS) block will be performed. The ultrasound transducer will be positioned at the distal thigh to identify the short head of the biceps femoris muscle and the lateral femoral cortex. A block needle will be advanced using an in-plane technique toward the fascial plane between the biceps femoris short head muscle and the lateral femoral cortex. After negative aspiration, local anesthetic will be injected into this fascial plane, and adequate spread will be confirmed using ultrasound imaging.

All patients will receive standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intravenous dexketoprofen 50 mg twice daily.

Ultrasound-guided adductor canal block will be performed using 10 mL of 0.25% bupivacaine.

Ultrasound-guided BiFeS block will be performed using 20 mL of 0.25% bupivacaine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Score
Time Frame: On the operation day

Pain will be assessed at rest using the visual analog scale on a scale from 0 (no pain) to 100 (worst pain). Pain assessment will be done at 6th hour after surgery.

On the operation day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Scores
Time Frame: On the operation day

Pain will be assessed at rest using the visual analog scale on a scale from 0 (no pain) to 100 (worst pain). Pain assessment will be done at 0st, 1st, 2nd, 12th, and 24th hours after surgery.

On the operation day
Total Postoperative Morphine Consumption During the First 24 Hours AfterSurgery
Time Frame: On the operation day

Total Postoperative Morphine Consumption During the First 24 HoursAfter Surgery

On the operation day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 5, 2026

Primary Completion (Estimated)

October 13, 2027

Study Completion (Estimated)

October 27, 2027

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 5, 2026

Study Record Updates

Last Update Posted (Actual)

October 8, 2026

Last Update Submitted That Met QC Criteria

October 5, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AEŞH-EK-2026-208

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.